Biochemical Characterization of Novel Germline BRAF and MEK Mutations in Cardio-Facio-Cutaneous Syndrome

Methods in Enzymology

Volumn 438, Issue , 2008, Pages 277-289

  Rodriguez Viciana, Pablo ^a   Rauen, Katherine A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAF PROTEIN; BRAF PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN;

CARDIO FACIO CUTANEOUS SYNDROME; CHEMICAL ANALYSIS; DEVELOPMENTAL DISORDER; DNA ISOLATION; ENZYME ACTIVITY; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; MUTANT; MUTATION; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PLASMID; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TRANSIENT TRANSFECTION; WESTERN BLOTTING; WILD TYPE; AMINO ACID SUBSTITUTION; ARTICLE; CONGENITAL HEART MALFORMATION; CONGENITAL SKIN DISEASE; CRANIOFACIAL MALFORMATION; GENETICS; SYNDROME;

AMINO ACID SUBSTITUTION; BLOTTING, WESTERN; CRANIOFACIAL ABNORMALITIES; HEART DEFECTS, CONGENITAL; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; PROTO-ONCOGENE PROTEINS B-RAF; RAF KINASES; SKIN ABNORMALITIES; SYNDROME;

EID: 45549096332     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(07)38019-1     Document Type: Review

References (19)

1. Alessi D.R., Cohen P., Ashworth A., Cowley S., Leevers S.J., and Marshall C.J. Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol. 255 (1995) 279-290
2. Bansal A., Ramirez R.D., and Minna J.D. Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene 14 (1997) 1231-1234
3. Belanger L.F., Roy S., Tremblay M., Brott B., Steff A.M., Mourad W., Hugo P., Erikson R., and Charron J. Mek2 is dispensable for mouse growth and development. Mol. Cell Biol. 23 (2003) 4778-4787
4. Cowley S., Paterson H., Kemp P., and Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77 (1994) 841-852
5. Estep A.L., Tidyman W.E., Teitell M.A., Cotter P.D., and Rauen K.A. HRAS mutations in Costello syndrome: Detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. A 140 (2006) 8-16
6. Giroux S., Tremblay M., Bernard D., Cardin-Girard J.F., Aubry S., Larouche L., Rousseau S., Huot J., Landry J., Jeannotte L., and Charron J. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9 (1999) 369-372
7. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., Shimada Y., Ari-i S., Wada H., Fujimoto J., and Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18 (1999) 813-822
8. Kratz C.P., Niemeyer C.M., and Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. J. Mol. Med. 85 (2007) 223-231
9. Mansour S.J., Matten W.T., Hermann A.S., Candia J.M., Rong S., Fukasawa K., Vande Woude G.F., and Ahn N.G. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265 (1994) 966-970
10. Narumi Y., Aoki Y., Niihori T., Neri G., Cave H., Verloes A., Nava C., Kavamura M.I., Okamoto N., Kurosawa K., Hennekam R.C., Wilson L.C., et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: Overlapping clinical manifestations with Costello syndrome. Am. J. Med. Genet. A 143 (2007) 799-807
11. Niihori T., Aoki Y., Narumi Y., Neri G., Cave H., Verloes A., Okamoto N., Hennekam R.C., Gillessen-Kaesbach G., Wieczorek D., Kavamura M.I., Kurosawa K., et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat. Genet. 38 (2006) 294-296
12. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., Salem G., Pohida T., et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
13. Rauen K.A. Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am. J. Med. Genet. A 140 (2006) 1681-1683
14. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., and Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311 (2006) 1287-1290
15. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4 (2004) 937-947
16. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., Sebolt-Leopold J., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
17. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., and Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116 (2004) 855-867
18. Yoon G., Rosenberg J., Blaser S., and Rauen K.A. Neurological complications of the cardio-facio-cutaneous syndrome (CFC). Developmental Medicine and Child Neurology 49 (2007) 894-899
19. Yoon S., and Seger R. The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors 24 (2006) 21-44